NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
4 trialsNCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated